TP53 and triple-negative breast carcinoma: The high levels of DAPK1 in this aggressive subtype posed questions that prompted further investigations which concluded that high DAPK1 expression correlated positively with mutations in TP53 and is abundant in ER-negative breast cancers, especially for triple negative breast cancers (TNBC) [30].